Abstract | BACKGROUND: METHODS: In this retrospective cohort study, we included KTRs who suffered from AA amyloidosis caused by FMF and treated with anakinra or canakinumab (study group, n = 36). Using propensity score matching, we selected 36 patients without FMF or amyloidosis from our database of 696 KTRs as the control group. Primary outcomes were patient and graft survival. Biopsy-confirmed graft rejection, changes in estimated glomerular filtration rate (eGFR), high-sensitivity CRP ( hsCRP), erythrocyte sedimentation rate (ESR), proteinuria and number of monthly attacks were secondary outcomes. RESULTS: All KTRs with FMF began IL-1 blocker therapy with anakinra and nine (25%) were switched to canakinumab. Overall death was more frequent in the study group (19.4% vs 0%) (P = .005); however, overall graft loss was comparable between study (27.8%) and control groups (36.1%) (P = .448). Five- and 10-year graft survival rates were significantly higher in the study group (94.4% and 83.3%, respectively) than in the control group (77.8% and 63.9%, respectively) (P = .014 and P < .001, respectively). Rejections were numerically lower in study group (8.3% vs 25%), but it did not reach to statistical significance (P = .058). When compared with the pre-treatment period, with IL-1 blockers, the number of attacks per month (P < .001), and eGFR (P = .004), hsCRP (P < .001) and ESR (P = .026) levels were lower throughout the follow-up, whereas proteinuria levels were not. CONCLUSIONS:
Anakinra and canakinumab are effective in KTRs suffering from FMF; however, the mortality rate may be of concern.
|
Authors | Safak Mirioglu, Ahmet Burak Dirim, Murat Bektas, Erol Demir, Yavuz Burak Tor, Yasemin Ozluk, Isin Kilicaslan, Ozgur Akin Oto, Yasemin Yalcinkaya, Yasar Caliskan, Bahar Artim-Esen, Halil Yazici, Murat Inanc, Aydin Turkmen, Ahmet Gul, Mehmet Sukru Sever |
Journal | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
(Nephrol Dial Transplant)
Vol. 38
Issue 5
Pg. 1327-1336
(05 04 2023)
ISSN: 1460-2385 [Electronic] England |
PMID | 36542475
(Publication Type: Journal Article)
|
Copyright | © The Author(s) 2022. Published by Oxford University Press on behalf of the ERA. |
Chemical References |
- Colchicine
- Interleukin 1 Receptor Antagonist Protein
- Interleukin-1
- C-Reactive Protein
|
Topics |
- Humans
- Familial Mediterranean Fever
(complications, drug therapy)
- Cohort Studies
- Colchicine
- Interleukin 1 Receptor Antagonist Protein
(therapeutic use)
- Kidney Transplantation
(adverse effects)
- Interleukin-1
- Retrospective Studies
- C-Reactive Protein
- Propensity Score
- Proteinuria
(complications)
|